參考文獻 |
REFERENCES
1. He, Y., et al., Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. Journal of clinical microbiology, 2004. 42(11): p. 5309-5314.
2. Che, X.-Y., et al., Nucleocapsid protein as early diagnostic marker for SARS. Emerging infectious diseases, 2004. 10(11): p. 1947.
3. Masters, P.S. and L.S. Sturman, Background paper functions of the coronavirus nucleocapsid protein. Coronaviruses and their Diseases, 1990: p. 235-238.
4. Pan, P., et al., SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nature Communications, 2021. 12(1): p. 1-17.
5. Karwaciak, I., et al., Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes and Macrophages—Potential Implications for Cytokine Storm Syndrome. Vaccines, 2021. 9(1): p. 54.
6. Surjit, M. and S.K. Lal, The SARS-CoV nucleocapsid protein: a protein with multifarious activities. Infection, genetics and evolution, 2008. 8(4): p. 397-405.
7. Zhang, X., et al., Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-κB. Virology, 2007. 365(2): p. 324-335.
8. Tong, S., et al., Direct sequencing of SARS-coronavirus S and N genes from clinical specimens shows limited variation. The Journal of infectious diseases, 2004. 190(6): p. 1127-1131.
9. Dutta, N.K., K. Mazumdar, and J.T. Gordy, The nucleocapsid protein of SARS–CoV-2: a target for vaccine development. Journal of virology, 2020. 94(13): p. e00647-20.
10. Okba, N.M., et al., Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients. Emerging infectious diseases, 2020. 26(7): p. 1478.
11. Chi, Z., et al., The Cytokine Release Syndrome (CRS) of Severe COVID-19 and Interleukin-6 Receptor (IL-6R) Antagonist Tocilizumab man be the Key to Reduce the Mortality. Int J Antimicrob Agents, 2020.
12. Lu, R., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet, 2020. 395(10224): p. 565-574.
13. Vatansever, H.S. and E. Becer, Relationship between IL-6 and COVID-19: to be considered during treatment. Future Virology, 2020. 15(12): p. 817-822.
14. Ulhaq, Z.S. and G.V. Soraya, Interleukin-6 as a potential biomarker of COVID-19 progression. Medecine et maladies infectieuses, 2020. 50(4): p. 382.
15. Spacova, I., et al., Topical Microbial Therapeutics against Respiratory Viral Infections. Trends in Molecular Medicine, 2021.
16. Chen, H.-W., et al., Nasal commensal Staphylococcus epidermidis counteracts influenza virus. Scientific reports, 2016. 6(1): p. 1-12.
17. Ji, J.Y., et al., The Nasal Symbiont Staphylococcus epidermidis Restricts the Transcription of SARS-CoV-2 Entry Factors in Human Nasal Epithelium. Staphylococcus Epidermidis, 2021.
18. Kim, H.J., et al., Nasal commensal Staphylococcus epidermidis enhances interferon-λ-dependent immunity against influenza virus. Microbiome, 2019. 7(1): p. 1-12.
19. Jo, A., et al., Nasal commensal, Staphylococcus epidermidis shapes the mucosal environment to prevent influenza virus invasion through Serpine1 induction. bioRxiv, 2020.
20. Costela-Ruiz, V.J., et al., SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine & growth factor reviews, 2020. 54: p. 62-75.
21. Wu, F., et al., A new coronavirus associated with human respiratory disease in China. Nature, 2020. 579(7798): p. 265-269.
22. Fehr, A.R. and S. Perlman, Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses, 2015: p. 1-23.
23. Chen, Y., et al., Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2′-O-methylation by nsp16/nsp10 protein complex. PLoS pathogens, 2011. 7(10): p. e1002294.
24. Galanopoulos, M., A. Doukatas, and M. Gazouli, Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract. World journal of gastroenterology, 2020. 26(41): p. 6335.
25. Cascella, M., et al., Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls, 2021.
26. Chen, Y., Q. Liu, and D. Guo, Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of medical virology, 2020. 92(4): p. 418-423.
27. Siu, Y., et al., The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. Journal of virology, 2008. 82(22): p. 11318-11330.
28. Bai, Z., et al., The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses, 2021. 13(6): p. 1115.
29. Chang, C.-k., et al., The SARS coronavirus nucleocapsid protein–forms and functions. Antiviral research, 2014. 103: p. 39-50.
30. Peng, T.Y., K.R. Lee, and W.Y. Tarn, Phosphorylation of the arginine/serine dipeptide‐rich motif of the severe acute respiratory syndrome coronavirus nucleocapsid protein modulates its multimerization, translation inhibitory activity and cellular localization. The FEBS journal, 2008. 275(16): p. 4152-4163.
31. Sontheimer, R.D., Skin is not the largest organ. The Journal of investigative dermatology, 2014. 134(2): p. 581.
32. Zhou, H., et al., Applications of Human Skin Microbiota in the Cutaneous Disorders for Ecology-Based Therapy. Frontiers in Cellular and Infection Microbiology, 2020. 10.
33. Belkaid, Y. and J.A. Segre, Dialogue between skin microbiota and immunity. Science, 2014. 346(6212): p. 954-959.
34. Balasubramaniam, A., et al., Skin bacteria mediate glycerol fermentation to produce electricity and resist UV-B. Microorganisms, 2020. 8(7): p. 1092.
35. Brown, M.M. and A.R. Horswill, Staphylococcus epidermidis—Skin friend or foe? PLoS Pathogens, 2020. 16(11): p. e1009026.
36. Pastar, I., et al., Staphylococcus epidermidis boosts innate immune response by activation of Gamma Delta T cells and induction of Perforin-2 in human skin. Frontiers in immunology, 2020. 11: p. 2253.
37. Iwase, T., et al., Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature, 2010. 465(7296): p. 346-349.
38. Wang, Y., et al., Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgaris. Applied microbiology and biotechnology, 2014. 98(1): p. 411-424.
39. Marito, S., et al., Electricity-producing Staphylococcus epidermidis counteracts Cutibacterium acnes. Scientific reports, 2021. 11(1): p. 1-11.
40. Balasubramaniam, A., et al., Repurposing INCI-registered compounds as skin prebiotics for probiotic Staphylococcus epidermidis against UV-B. Scientific reports, 2020. 10(1): p. 1-10.
41. Keshari, S., et al., Butyric acid from probiotic staphylococcus epidermidis in the skin microbiome down-regulates the ultraviolet-induced pro-inflammatory IL-6 cytokine via short-chain fatty acid receptor. International journal of molecular sciences, 2019. 20(18): p. 4477.
42. Nakatsuji, T., et al., A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Science Advances, 2018. 4(2): p. eaao4502.
43. Negari, I.P., S. Keshari, and C.-M. Huang, Probiotic activity of Staphylococcus epidermidis induces collagen type I production through FFaR2/p-ERK Signaling. International journal of molecular sciences, 2021. 22(3): p. 1414.
44. Light, S.H., et al., A flavin-based extracellular electron transfer mechanism in diverse Gram-positive bacteria. Nature, 2018. 562(7725): p. 140-144.
45. Vinolo, M.A., et al., Regulation of inflammation by short chain fatty acids. Nutrients, 2011. 3(10): p. 858-876.
46. Uribe-Alvarez, C., et al., Staphylococcus epidermidis: metabolic adaptation and biofilm formation in response to different oxygen concentrations. FEMS Pathogens and Disease, 2016. 74(1): p. ftv111.
47. Light, S.H., et al., Extracellular electron transfer powers flavinylated extracellular reductases in Gram-positive bacteria. Proceedings of the National Academy of Sciences, 2019. 116(52): p. 26892-26899.
48. Tanaka, K., et al., Extracellular electron transfer via outer membrane cytochromes in a methanotrophic bacterium Methylococcus capsulatus (Bath). Frontiers in microbiology, 2018. 9: p. 2905.
49. Kato, S., Biotechnological aspects of microbial extracellular electron transfer. Microbes and environments, 2015: p. ME15028.
50. Cahoon, L.A. and N.E. Freitag, The electrifying energy of gut microbes. 2018, Nature Publishing Group.
51. Leja, K., K. Czaczyk, and K. Myszka, Biotechnological synthesis of 1, 3-propanediol using Clostridium ssp. African Journal of Biotechnology, 2011. 10(54): p. 11093-11101.
52. Du Toit, A., Exporting electrons. Nature Reviews Microbiology, 2018. 16(11): p. 657-657.
53. Nakatani, Y., et al., Unprecedented properties of phenothiazines unraveled by a NDH-2 bioelectrochemical assay platform. Journal of the American Chemical Society, 2019. 142(3): p. 1311-1320.
54. Hiraishi, A., High‐performance liquid chromatographic analysis of demethylmenaquinone and menaquinone mixtures from bacteria. Journal of applied bacteriology, 1988. 64(2): p. 103-105.
55. Bacher, A., Riboflavin kinase and FAD synthetase, in Chemistry and biochemistry of flavoenzymes. 2018, CRC press. p. 349-370.
56. Averianova, L.A., et al., Production of vitamin B2 (riboflavin) by microorganisms: An overview. Frontiers in Bioengineering and Biotechnology, 2020. 8.
57. Suwannasom, N., et al., Riboflavin: The health benefits of a forgotten natural vitamin. International Journal of Molecular Sciences, 2020. 21(3): p. 950.
58. Liu, S., et al., Production of riboflavin and related cofactors by biotechnological processes. Microbial cell factories, 2020. 19(1): p. 1-16.
59. Vandamme, E.J. and J.L. Revuelta, Industrial biotechnology of vitamins, biopigments, and antioxidants. 2016: John Wiley & Sons.
60. Jaeger, B. and A.M. Bosch, Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience. Journal of inherited metabolic disease, 2016. 39(4): p. 559-564.
61. Litwack, G., Chapter 20-Vitamins and nutrition. Human Biochemistry, 2018: p. 645-680.
62. McDowell, L.R., Vitamins in animal and human nutrition. 2000: John Wiley & Sons.
63. Saedisomeolia, A. and M. Ashoori, Riboflavin in human health: a review of current evidences. Advances in food and nutrition research, 2018. 83: p. 57-81.
64. Mahabadi, N., A. Bhusal, and S.W. Banks, Riboflavin Deficiency. StatPearls [Internet], 2020.
65. Thiamin, R., Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline1. 1998.
66. Ashoori, M. and A. Saedisomeolia, Riboflavin (vitamin B2) and oxidative stress: a review. British journal of nutrition, 2014. 111(11): p. 1985-1991.
67. Mazur-Bialy, A.I., B. Buchala, and B. Plytycz, Riboflavin deprivation inhibits macrophage viability and activity–a study on the RAW 264.7 cell line. British journal of nutrition, 2013. 110(3): p. 509-514.
68. Al-Harbi, N.O., et al., Riboflavin attenuates lipopolysaccharide-induced lung injury in rats. Toxicology mechanisms and methods, 2015. 25(5): p. 417-423.
69. NAKAJIMA, H., Y. ISHIDO, and G. IMOKAWA, Flavin mononucleotide attenuates the UVA-induced up-regulation of matrix-metalloproteinase-1 and skin fibroblast elastase in human dermal fibroblasts. 皮膚の科学, 2010. 9(5): p. 442-451.
70. Lim, S.H., J.S. Choi, and E.Y. Park, Microbial production of riboflavin using riboflavin overproducers, Ashbya gossypii, Bacillus subtilis, and Candida famate: an overview. Biotechnology and Bioprocess Engineering, 2001. 6(2): p. 75-88.
71. Mack, M., A.P. van Loon, and H.-P. Hohmann, Regulation of riboflavin biosynthesis in Bacillus subtilis is affected by the activity of the flavokinase/flavin adenine dinucleotide synthetase encoded by ribC. Journal of bacteriology, 1998. 180(4): p. 950-955.
72. You, L.-X., et al., Flavins mediate extracellular electron transfer in Gram-positive Bacillus megaterium strain LLD-1. Bioelectrochemistry, 2018. 119: p. 196-202.
73. Tian, T., et al., Flavin-mediated extracellular electron transfer in Gram-positive bacteria Bacillus cereus DIF1 and Rhodococcus ruber DIF2. RSC Advances, 2019. 9(70): p. 40903-40909.
74. Sebastián, M., et al., The biosynthesis of flavin cofactors in Listeria monocytogenes. Journal of molecular biology, 2019. 431(15): p. 2762-2776.
75. Liu, S., et al., Modular engineering of the flavin pathway in Escherichia coli for improved flavin mononucleotide and flavin adenine dinucleotide production. Journal of agricultural and food chemistry, 2019. 67(23): p. 6532-6540.
76. Taniguchi, H. and V.F. Wendisch, Exploring the role of sigma factor gene expression on production by Corynebacterium glutamicum: sigma factor H and FMN as example. Frontiers in microbiology, 2015. 6: p. 740.
77. Pallotta, M.L., Riboflavin/Vitamin B2 and Lactic Acid Bacteria. EC Microbiology ECO, 2019. 2(2019): p. 03-06.
78. Pedrolli, D.B., et al., A dual control mechanism synchronizes riboflavin and sulphur metabolism in Bacillus subtilis. Proceedings of the National Academy of Sciences, 2015. 112(45): p. 14054-14059.
79. Schlüpen, C., et al., Disruption of the SHM2 gene, encoding one of two serine hydroxymethyltransferase isoenzymes, reduces the flux from glycine to serine in Ashbya gossypii. Biochemical Journal, 2003. 369(2): p. 263-273.
80. Revuelta, J.L., R. Ledesma-Amaro, and A. Jiménez, Industrial production of vitamin B2 by microbial fermentation. Industrial biotechnology of vitamins, biopigments, and antioxidants, 2016: p. 15-40.
81. Rodionova, I.A., et al., A novel bifunctional transcriptional regulator of riboflavin metabolism in Archaea. Nucleic acids research, 2017. 45(7): p. 3785-3799.
82. Pedrolli, D.B., et al., The antibiotics roseoflavin and 8-demethyl-8-amino-riboflavin from Streptomyces davawensis are metabolized by human flavokinase and human FAD synthetase. Biochemical pharmacology, 2011. 82(12): p. 1853-1859.
83. Jankowitsch, F., et al., Genome sequence of the bacterium Streptomyces davawensis JCM 4913 and heterologous production of the unique antibiotic roseoflavin. Journal of bacteriology, 2012. 194(24): p. 6818-6827.
84. Mansjö, M. and J. Johansson, The Riboflavin analog Roseoflavin targets an FMN-riboswitch and blocks Listeria monocytogene s growth, but also stimulates virulence gene-expression and infection. RNA biology, 2011. 8(4): p. 674-680.
85. Otani, S., et al., Roseoflavin, a new antimicrobial pigment from Streptomyces. The Journal of antibiotics, 1974. 27(1): p. 88-89.
86. Pedrolli, D.B., et al., A highly specialized flavin mononucleotide riboswitch responds differently to similar ligands and confers roseoflavin resistance to Streptomyces davawensis. Nucleic acids research, 2012. 40(17): p. 8662-8673.
87. Grill, S., et al., The bifunctional flavokinase/flavin adenine dinucleotide synthetase from Streptomyces davawensis produces inactive flavin cofactors and is not involved in resistance to the antibiotic roseoflavin. Journal of bacteriology, 2008. 190(5): p. 1546-1553.
88. Otani, S., S. Kasai, and K. Matsui, [34] Isolation, chemical synthesis, and properties of roseoflavin, in Methods in enzymology. 1980, Elsevier. p. 235-241.
89. Langer, S., et al., Flavoproteins are potential targets for the antibiotic roseoflavin in Escherichia coli. Journal of bacteriology, 2013. 195(18): p. 4037-4045.
90. Stepanov, A., et al., Analgos of riboflavin, lumiflavin and alloxazine derivatives. II. Effect of roseoflavin on 6, 7-dimethyl-8-ribityllumazine and riboflavin synthetase synthesis and growth of Bacillus subtilis. Genetika, 1977. 13(3): p. 490-495.
91. Von Canstein, H., et al., Secretion of flavins by Shewanella species and their role in extracellular electron transfer. Applied and environmental microbiology, 2008. 74(3): p. 615-623.
92. Lee, E.R., K.F. Blount, and R.R. Breaker, Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA biology, 2009. 6(2): p. 187-194.
93. Tang, Y., et al., Cytokine storm in COVID-19: the current evidence and treatment strategies. Frontiers in immunology, 2020. 11: p. 1708.
94. Song, P., et al., Cytokine storm induced by SARS-CoV-2. Clinica chimica acta, 2020. 509: p. 280-287.
95. Ley, K., et al., How mouse macrophages sense what is going on. Frontiers in immunology, 2016. 7: p. 204.
96. Wang, J.P., et al., Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. Journal of virology, 2005. 79(20): p. 12658-12666.
97. Zhang, X. and D. Mosser, Macrophage activation by endogenous danger signals. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2008. 214(2): p. 161-178.
98. Tseng, C.-T.K., et al., Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. The Journal of Immunology, 2005. 174(12): p. 7977-7985.
99. Traisaeng, S., et al., A derivative of butyric acid, the fermentation metabolite of Staphylococcus epidermidis, inhibits the growth of a Staphylococcus aureus strain isolated from atopic dermatitis patients. Toxins, 2019. 11(6): p. 311.
100. Schwechheimer, S.K., et al., Biotechnology of riboflavin. Applied microbiology and biotechnology, 2016. 100(5): p. 2107-2119.
101. Rosenbaum, M., et al., Cathodes as electron donors for microbial metabolism: which extracellular electron transfer mechanisms are involved? Bioresource technology, 2011. 102(1): p. 324-333.
102. Guthrie, J.W., General considerations when dealing with biological fluid samples In Pawliszyn (Ed.), Comprehensive sampling and sample preparation (Vol. 3, pp. 1–19). Cambridge, MA: Academic Press. 2012. doi: 10.1016/B978-0-12-381373-2.00065-X
103. Ravanel, K., et al., Measles virus nucleocapsid protein binds to FcγRII and inhibits human B cell antibody production. The journal of experimental medicine, 1997. 186(2): p. 269-278.
104. Yang, J.J., et al., Production of electricity and reduction of high-fat diet-induced IL-6 by glucose fermentation of Leuconostoc mesenteroides. Biochemical and Biophysical Research Communications,2020. 533(4): p. 651-656.
105. Oschman, J.L., Can electrons act as antioxidants? A review and commentary. The Journal of Alternative and Complementary Medicine, 2007. 13(9): p. 955-967.
106. Lee, A.-J., K.-J. Cho, and J.-H. Kim, MyD88–BLT2-dependent cascade contributes to LPS-induced interleukin-6 production in mouse macrophage. Experimental & molecular medicine, 2015. 47(4): p. e156-e156. |